Abstract | AIM: METHODS: KK-A(y)/Ta mice were divided into 2 groups as follows: pyridoxamine treatment group and a tap water group as controls. The urinary ACR, fasting serum insulin, TG and lipoprotein subclasses were measured as biochemical parameters. The renal expressions of malondialdehyde (MDA) were evaluated by immunohistochemistry. CD36 mRNA expressions in kidney and adipose tissue were also evaluated using real-time PCR. RESULTS:
Pyridoxamine decreased levels of urinary ACR, serum TG, especially VLDL and fasting serum insulin. MDA accumulation in the pyridoxamine treated group was significantly lower than those in the non-treatment group. The CD36 accumulation and mRNA expressions in kidney and adipose tissue in the treatment group were significantly higher than those in the non-treatment group. CONCLUSIONS:
|
Authors | Maki Murakoshi, Mitsuo Tanimoto, Tomohito Gohda, Shinji Hagiwara, Ikko Ohara, Hitoe Toyoda, Yuji Ishikawa, Satoshi Horikoshi, Yasuhiko Tomino |
Journal | Diabetes research and clinical practice
(Diabetes Res Clin Pract)
Vol. 83
Issue 2
Pg. 183-9
(Feb 2009)
ISSN: 1872-8227 [Electronic] Ireland |
PMID | 19144436
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- CD36 Antigens
- Hypoglycemic Agents
- Malondialdehyde
- Pyridoxamine
|
Topics |
- Adipose Tissue
(drug effects, metabolism)
- Animals
- CD36 Antigens
(genetics, metabolism)
- Diabetes Complications
(genetics, metabolism, prevention & control)
- Diabetes Mellitus, Experimental
(complications, genetics, metabolism)
- Diabetes Mellitus, Type 2
(complications, genetics, metabolism)
- Drug Evaluation, Preclinical
- Gene Expression Regulation
(drug effects)
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Insulin Resistance
(genetics)
- Kidney
(drug effects, metabolism)
- Lipid Peroxidation
(drug effects)
- Male
- Malondialdehyde
(metabolism)
- Mice
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Pyridoxamine
(pharmacology, therapeutic use)
|